Trials / Conditions / Chronic Idiopathic Urticaria

Chronic Idiopathic Urticaria

23 registered clinical trials studyying Chronic Idiopathic Urticaria — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. NCT07486583	Cairo University	Phase 3
Unknown	Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontane NCT04175704	United BioPharma	Phase 1
Completed	Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic NCT05774639	Kashiv BioSciences, LLC	Phase 3
Completed	Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria NCT05936567	Incyte Corporation	Phase 2
Completed	A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic D NCT03858634	Genentech, Inc.	Phase 2
Completed	Mast Cell Activation Test in Allergic Disease NCT03406325	Hong Kong Sanatorium & Hospital	—
Completed	Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody NCT03183024	Jonathan A. Bernstein, MD	Phase 4
Completed	Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urtic NCT02814630	Asthma Inc Clinical Research Center	N/A
Unknown	Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria NCT02166151	Rabin Medical Center	Phase 3
Completed	Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antag NCT02031679	Johns Hopkins University	Phase 2
Completed	Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Pa NCT01803763	Insel Gruppe AG, University Hospital Bern	Phase 2 / Phase 3
Unknown	Efficacy Study of Canakinumab to Treat Urticaria NCT01635127	University of Zurich	Phase 2
Completed	Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to NCT01599637	Novartis Pharmaceuticals	Phase 2
Completed	A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic NCT01292473	Genentech, Inc.	Phase 3
Completed	A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/ NCT01287117	Genentech, Inc.	Phase 3
Completed	A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomat NCT01264939	Genentech, Inc.	Phase 3
Withdrawn	Etanercept for the Treatment of Chronic Urticaria NCT01030120	University of Utah	Phase 2 / Phase 3
Completed	A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With NCT00866788	Genentech, Inc.	Phase 2
Completed	Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P0484 NCT00536380	Organon and Co	Phase 4
Unknown	The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria NCT00346606	Lotus Pharmaceutical	Phase 4
Completed	CUTE (Chronic Urticaria Treatment Evaluation) NCT00264303	UCB Pharma	Phase 4
Completed	A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147) NCT00783354	Organon and Co	Phase 4
Completed	Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of D NCT00757562	Organon and Co	Phase 3